drug
tebentafusp
Marketedupdated 3mo agoby $IMCR Immunocore Holdings plc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 1all catalysts(0)
nothing on the calendar yet
Trials studying tebentafusp
- phase2Neoadjuvant Tebentafusp for Uveal Melanoma
- phase2Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma
- phase2Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
- phase3Adjuvant Tebentafusp in High Risk Ocular Melanoma
- phase2Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
- phase3Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
- phase2Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma
- phase2Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma
News(2)
- Regeneron ends eye disease trial for anti-CD3 antibody following safety reviewRegeneron has hit the brakes on the phase 1/2a trial for an experimental eye inflammation treatment, following an adverse event that tilted the drug’s risk/benefit profile in the wrong direction.fiercebiotech · 7h ago
- Five-year survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase 3 trial (CT029)Five-year Phase III data show tebentafusp doubles survival in metastatic uveal melanoma, with ctDNA response predicting benefit beyond imaging and progression.onclive · 3mo ago
Data sources
last refreshed 33m ago
Found something off?
comments(0)
5-min edit window · permanent after that